Previous 10 | Next 10 |
- Enrollment in the pheNIX Study Marks First Gene Therapy Clinical Trial for PKU - BEDFORD, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has commenced enrollment of the Phase 1/2 pheNIX trial for...
Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...
Just weeks after Homology Medicines (NASDAQ: FIXX ) received investigational new drug clearance from the US Food and Drug Administration (FDA) for its gene therapy candidate, HMI-102, the company revealed on Tuesday (May 14) that the regulatory agency has now granted the candidate fast trac...
The FDA has granted Fast Track designation to Homology Medicines' (NASDAQ: FIXX ) HMI-102, its one-time gene therapy candidate for the treatment of adults with phenylketonuria (PKU). More news on: Homology Medicines, Inc., Healthcare stocks news, Read more ...
- Company Provides Details of pheNIX, the First Gene Therapy Trial for PKU, and Remains on Track to Report Initial Clinical Results from the Phase 1/2 Study in 2019 - BEDFORD, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, a...
Homology Medicines (NASDAQ: FIXX ): Q1 GAAP EPS of -$0.64 misses by $0.11 . More news on: Homology Medicines, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Received FDA Clearance for IND and Anticipate Starting Phase 1/2 pheNIX Trial for PKU Gene Therapy Candidate with Initial Data Expected by Year End - - Began IND-Enabling Studies for Two Additional Programs, Including First Gene Editing Program - - Strengthened Financial Pos...
BEDFORD, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate during a fireside chat at the 2019 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 1...
- Homology’s Scalable HEK293 Suspension Manufacturing Process for AAVHSCs Demonstrated Superiority to a Baculovirus System and AAVHSC15 Showed Improved In Vivo Efficacy Compared to AAV5 in PKU Model - - Non-clinical Tolerability Results of HMI-102 PKU Gene Therapy Candidate S...
BEDFORD, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data demonstrating that, with a single dose, the Company’s suite of novel adeno-associated virus vectors targeted c...
News, Short Squeeze, Breakout and More Instantly...
Homology Medicines Inc. Company Name:
FIXX Stock Symbol:
NASDAQ Market:
Homology Medicines Inc. Website:
2024-03-25 09:02:02 ET Homology Medicines Inc (FIXX) announced stock split at a ratio of 1-for-18 on 2024-03-25 ... Full story available on KlickAnalytics.com
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstandi...
Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“ Nasdaq Notif...